ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO129

Progression of Cardiovascular Calcification in Renal Transplant Recipients

Session Information

Category: Transplantation

  • 1802 Transplantation: Clinical

Authors

  • Yaseen, Maria, University of Kentucky, Lexington, Kentucky, United States
  • Mohamed, Amr El-Husseini, University of Kentucky, Lexington, Kentucky, United States
  • Ashqar, Bilal, University of Kentucky, Lexington, Kentucky, United States
  • Hassan, Waleed, University of Kentucky, Lexington, Kentucky, United States
  • Awad, Radwa, University of Kentucky, Lexington, Kentucky, United States
  • Lowry, Conor, University of Kentucky, Lexington, Kentucky, United States
  • Gedaly, Roberto, University of Kentucky, Lexington, Kentucky, United States
  • Davenport, Daniel, University of Kentucky, Lexington, Kentucky, United States
  • Lima, Florence, University of Kentucky, Lexington, Kentucky, United States
  • Malluche, Hartmut H., University of Kentucky, Lexington, Kentucky, United States
Background

Cardiovascular disease is the leading cause of death in renal transplant patients. We conducted a study to determine the progression of cardiovascular calcification in renal transplant recipients.

Methods

192-slice computed tomography was used to longitudinally examine abdominal and thoracic aortic calcification (AAC, TAC) and CAC in 34 renal transplant recipients at time of transplantation, at 6 months (n=28), and at 12 months (n=24). Univariate analyses were used to assess risk factors for CAC progression. Transplant patients were matched to 50 dialysis patients. Linear regression was used to adjust for baseline CAC in evaluating groups’ calcification progression.

Results

Boxplots for AAC, TAC and CAC scores are shown in fig. 1. Pre-transplant square root of CAC volume (SqrtCACVol) correlated with serum calcium (r=.44, p=.012), magnesium (r=.43, p=.018), male gender (r=.56, p=.001), CAD (r=.49, p=.004) and age (r=.65, p < .001), but not with presence of diabetes, phosphorous, or dialysis vintage. None of these variables were associated with 1-year changes in SqrtCACVol. In the matched groups, transplant patients gained less SqrtCACVol compared to dialysis patient (Transplant: 1.3, 95% CI -0.4 - 3.1; Dialysis: 3.9, 95% CI 1.9 – 5.9, fig. 2), though this difference was not significant (p = 0.07).

Conclusion

Renal transplantation does not stop or reverse vascular calcification; however the rate of progression was less compared to dialysis patients.